Drug Type Monoclonal antibody |
Synonyms RO7790121 |
Target |
Mechanism VEGI modulators(Tumor necrosis factor superfamily member 15 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ulcerative colitis, active moderate | Phase 3 | US | 17 Sep 2024 | |
Crohn Disease | Phase 2 | US | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | BE | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | BG | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | CA | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | FR | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | DE | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | HU | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | PL | - | 24 Jul 2023 |
Crohn Disease | Phase 2 | SK | - | 24 Jul 2023 |